Floatz logo

Moxetumomab Pasudotox

Lymphosarcoma

MedImmune LLCantibody_drug_conjugatePhase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lymphosarcoma cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Moxetumomab Pasudotox is also rated in:

acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →